switching between glp-1 agonists ada Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance Glucagon-Like Peptide-1 Receptor Agonist Use

Policy Compared with the GLP-1 receptor agonist dulaglutide, the dual GLP-1/GIP receptor agonist tirzepatide was associated with a 14% lower incidence ( P 25 kg/m and HbA1c between 7.0% and 10.5%

Since then, additional studies of alcohol-dependent male rats have confirmed this reduction in alcohol drinking following acute Ex4, GLP-1, or liraglutide injection (Davis et al., 2012

The Glucagon-Like Peptide-1 Receptoror Not

& Caete, J

FDA guidance should help distinguish between noncompliant and clinically justified compounded formulations, supporting prescribers who have legitimate reasons for seeking tailored options